Reckitt Benckiser (United States)

The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment

Ferdinand C. Breedveld, Michael H. Weisman, Arthur F. Kavanaugh et al. · Arthritis & Rheumatism · 2005 · 1.8K citations

Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial

Michael E. Weinblatt, Edward Keystone, Daniel E. Furst et al. · Arthritis & Rheumatism · 2003 · 1.8K citations

Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial

Stephen B. Hanauer, William J. Sandborn, Paul Rutgeerts et al. · Gastroenterology · 2006 · 1.7K citations

Inflammation, Chronic Inflammatory Diseases, Autoimmune Disease +10

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial

Edward Keystone, Arthur F. Kavanaugh, John T. Sharp et al. · Arthritis & Rheumatism · 2004 · 1.2K citations

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial

Désirée van der Heijde, Alan Kivitz, Michael Schiff et al. · Arthritis & Rheumatism · 2006 · 874 citations